The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer
- PMID: 28356761
- PMCID: PMC5367898
- DOI: 10.2147/OTT.S132806
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer
Retraction in
-
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction].Onco Targets Ther. 2017 May 4;10:2425. doi: 10.2147/OTT.S140498. eCollection 2017. Onco Targets Ther. 2017. PMID: 28496341 Free PMC article.
Abstract
Objective: HER2 overexpression is associated with aggressive phenotypes in breast cancer, including increased tumor proliferation, greater invasiveness, and reduced overall survival. The overall response rate to HER2-targeted therapies remains <30%. There is an urgent need for the identification of efficient markers to predict patients with a poor prognosis. This study was designed to investigate the correlation between EphB4 and EphrinB2 expression and the clinicopathological characteristics of HER2-positive breast cancer.
Materials and methods: A total of 111 primary HER2-positive breast cancer patients were enrolled in this study (diagnosed since December 2005 to November 2010 from the Second Hospital of Dalian Medical University). The protein expression of EphB4 and EphrinB2 was examined by immunohistochemistry using paraffin-embedded tumor tissues.
Results: There was a significant correlation between EphB4 and EphrinB2 expression (P=0.013, r=0.255). Kaplan-Meier analysis showed that the prognosis of patients with a high expression of both EphB4 and EphrinB2 was significantly worse than the prognosis of patients with either EphB4 or EphrinB2 expression and patients with negative expression (hazard ratio [HR] =1.935, P=0.0224). However, high expression of EphB4 or EphrinB2 alone was not an independent prognostic factor to predict worse overall survival. To summarize, HER2-positive breast cancer patients with overexpression of both EphB4 and EphrinB2 were associated with the worst prognosis.
Conclusion: High expression of EphB4 and EphrinB2 correlated with poor overall survival, which can serve as an independent prognostic indicator in primary HER2-positive breast cancer patients.
Keywords: EphB4; EphrinB2; breast carcinoma; prognosis.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures
References
-
- Sharma GK, Dhillon VK, Masood R, Maceri DR. Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: a pilot study. Head Neck. 2015;37(7):964–969. - PubMed
-
- Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers. Ann Oncol. 2007;18(3):485–490. - PubMed
-
- Yang D, Jin C, Ma H, et al. EphrinB2/EphB4 pathway in postnatal angiogenesis: a potential therapeutic target for ischemic cardiovascular disease. Angiogenesis. 2016;19(3):297–309. - PubMed
-
- Tu Y, He S, Fu J, et al. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients. Clin Transl Oncol. 2012;14(3):214–220. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
